Teva Pharmaceutical Industries Ltd., Actavis plc, and Mylan Inc. each have launched a generic equivalent to Celebrex (celecoxib) in the United States. Each company is offering 50, 100, 200, and 400 mg strengths of celecoxib. 

Celebrex is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Celebrex, marketed by Pfizer, had annual sales of approximately $2.56 billion in the United States, according to IMS data as of October 2014 and as reported by Teva.

Source: Teva Pharmaceutical Industries , Actavis, and Mylan